M&G PLC Buys 84,820 Shares of Elevance Health, Inc. $ELV

M&G PLC raised its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 9.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,015,113 shares of the company’s stock after purchasing an additional 84,820 shares during the period. Elevance Health accounts for 1.7% of M&G PLC’s portfolio, making the stock its 7th largest position. M&G PLC owned about 0.46% of Elevance Health worth $327,881,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Physician Wealth Advisors Inc. grew its stake in shares of Elevance Health by 331.6% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after buying an additional 63 shares during the period. Activest Wealth Management boosted its holdings in Elevance Health by 66.7% in the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after acquiring an additional 34 shares during the last quarter. Vermillion & White Wealth Management Group LLC grew its position in Elevance Health by 94.9% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock valued at $30,000 after acquiring an additional 37 shares during the period. BOK Financial Private Wealth Inc. acquired a new stake in Elevance Health during the second quarter worth about $32,000. Finally, Motco raised its holdings in shares of Elevance Health by 334.8% in the 3rd quarter. Motco now owns 100 shares of the company’s stock worth $32,000 after purchasing an additional 77 shares during the period. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Analysts Set New Price Targets

ELV has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $332.00 target price on shares of Elevance Health in a research report on Thursday, January 29th. Wolfe Research set a $425.00 price objective on shares of Elevance Health and gave the stock an “outperform” rating in a research report on Thursday, January 8th. Barclays reduced their target price on shares of Elevance Health from $404.00 to $393.00 and set an “overweight” rating on the stock in a report on Friday, January 30th. UBS Group set a $400.00 price target on Elevance Health in a report on Thursday, January 29th. Finally, Mizuho set a $413.00 target price on shares of Elevance Health in a research report on Friday, January 9th. Twelve investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $390.55.

More Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks raised its Q4 2027 EPS forecast to $4.75 (from $3.48), a sign that Zacks expects stronger late‑year profitability which could support the stock if sustained. Elevance Health (ELV) on MarketBeat
• Neutral Sentiment: MSN ran a stock‑perspective piece highlighting two reasons to like ELV and one caveat; the article reinforces bullish arguments around Elevance’s scale and business stability but also flags at least one risk investors should weigh. 2 reasons to like ELV (and 1 not so much)
• Negative Sentiment: Zacks issued multiple cuts to near‑term and full‑year estimates — lowering FY2026 (to $25.53 from $29.01), FY2027 (to $28.40 from $31.89) and trimming several Q1/Q2 2026–2027 quarterly forecasts — which signals weaker expected growth in the coming quarters and is a potential headwind for the stock. Zacks Research Lowers Earnings Estimates for Elevance Health

Elevance Health Stock Up 3.1%

ELV stock opened at $346.49 on Monday. The firm has a market cap of $76.47 billion, a price-to-earnings ratio of 13.79, a PEG ratio of 1.93 and a beta of 0.50. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $458.75. The firm has a fifty day moving average price of $352.22 and a two-hundred day moving average price of $332.30. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. The company had revenue of $49.31 billion during the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.Elevance Health’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Research analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be given a $1.72 dividend. The ex-dividend date is Tuesday, March 10th. This represents a $6.88 annualized dividend and a yield of 2.0%. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s payout ratio is 27.23%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.